Researchers at Beijing Tiantan Hospital analyzed 101 glioma cases involving the brain’s motor pathway and found that ...
Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor ...
Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day December 10, 2025 1:00 PM ...
Base Case shows US$424M post tax NPV5, 33.1% IRR, with a 2.3 year payback at a US$2,300/oz gold price Upside Case shows US$972M post tax NPV5, 59.3% IRR, with a 1.4 year payback at a US$3,900/oz gold ...
BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS®) Phase 3 study ...
22h
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)
(GLOBE NEWSWIRE) -- (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback